Metamucil Multi-health benefits
Metamucil® gives your patients health benefits of psyllium fibre that go beyond irregularity:
- - Helps to suppress appetite before a meal
- - Helps lower cholesterol† to promote heart health
Above benefits apply to Metamucil Powder variants only
† Lowers mildly to moderately elevated cholesterol levels when taken with a low-fat diet
Metamucil improves serum lipid profiles
MEAN % CHANGE: SIGNIFICANT SERUM LIPID REDUCTION VS. PLACEBO1
MEAN % CHANGE: SIGNIFICANT SERUM LIPID REDUCTION VS. PLACEBO1
There was a significant reduction in mean total and LDL cholesterol for Metamucil vs. placebo in hypercholesterolemic patients over 6 months:1
- - 4.7% lower Total-C with Metamucil vs. placebo (p<0.001)
- - 6.7% lower LDL-C with Metamucil vs. placebo (p<0.001)
META-ANALYSIS: METAMUCIL PROVIDES SIGNIFICANT SERUM LIPID REDUCTION VS. PLACEBO2 §
There was a significant reduction in total and LDL cholesterol for Metamucil vs. placebo in a meta-analysis of 8 RCTs, after 8 weeks:2
- - 3.8% lower Total-C with Metamucil vs. placebo (p<0.0001)
- - 6.8% lower LDL-C with Metamucil vs. placebo (p<0.0001)
Metamucil: sustained satiety
Greater fullness for 4 hours between meals with Metamucil vs. placebo
STUDY 1 INVESTIGATED SATIETY EFFECTS OF METAMUCIL VS. PLACEBO WITH NORMAL MEALS3||,††
- - Increased mean fullness from meals with Metamucil vs. placebo, over 4 hours
VAS – Desire to Eat Scale/Hunger Scale results
- - Hunger and desire to eat were consistently and significantly (P≤0.007) reduced for Metamucil vs. placebo††
- - There were no serious adverse events, or withdrawals due to adverse events, in the study
Study 2 confirms 4-hour satiety3 ‡‡
STUDY 2 CONFIRMED STUDY 1 SATIETY BENEFITS IN PATIENTS CONSUMING AN ENERGY-RESTRICTED BREAKFAST WITH 6.8 g OF METAMUCIL VS. PLACEBO
- - The SLIM Scale showed an increased mean fullness between meals with Metamucil vs. placebo, consistent over 4 hours
VAS Scales showed results similar to Study
- - Significant reductions were seen in 3-day mean hunger and desire to eat VAS results for the Metamucil group vs placebo (p ≤ 0.008)
- - The energy-restricted meal in Study 2 resulted in a decreased satiation response to the meal for both Metamucil and placebo
No serious AE or withdrawals due to AE occurred. Mild AEs were similar, with each group reporting 3 events.
METAMUCIL WITH BREAKFASTS INCREASED FULLNESS3
Fullness from breakfast was 33% greater when patients took Metamucil vs. placebo
- - Metamucil’s decrease on the Mean VAS hunger scores was proportional to the decreased hunger from the meal. Metamucil decreased hunger by an additional 1/3 of the effect of the meal.
COMBINED RESULTS OF 6.8g METAMUCIL IN STUDY 1 & 23‖,‡‡
There were no serious AEs, or withdrawals due to AEs, reported in either study3
Metamucil supplementation before meals was well-tolerated and significantly increased satiety by: 3
- > Increasing fullness
- > Decreasing hunger
- > Reducing the desire to eat between meals
1. Anderson JW et al. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 2000;71(6):1433-8.
2. Anderson JW et al. Cholesterol lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000;71(2):472-9.
3. Brum JM et al. Satiety effects of psyllium in healthy volunteers. Appetite 2016;(105):27–36.
†A double-blind, placebo-controlled, parallel, multicenter study evaluated the long-term effectiveness of Metamucil (5.1 grams twice daily, n= 197) and cellulose placebo (5.1 grams twice daily n= 51), as an adjunct to diet in the treatment of patients with primary hypercholesterolemia. Eligible patients completed an 8-week dietary adaptation phase with dietician counselling on AHA step 1 diet (weeks -8 to -1) followed by a 26-week treatment phase (weeks 0–26) and continued AHA step 1 diet with counselling.
§A meta-analysis of 8 pivotal efficacy trials was conducted to evaluate the hypercholesterolemic effects of Metamucil (10.2 grams daily, n=384) and placebo (10.2 grams daily n=272) adjunctive to a low-fat diet for ≥ 8 weeks in individuals with mild-to-moderate hypercholesterolemia after a low-fat diet lead-in phase lasting ≥ 8 weeks.
||Study 1: A single center, randomized, double-blind, placebo-controlled, 4-way cross-over study enrolled 30 healthy patients (19 men/11 women), 28 patients completed the study. Patients were randomized to 4 different groups: placebo and 3 different doses of psyllium fibre (3.4 g, 6.8 g, and 10.2 g) were taken before a controlled, regular breakfast and lunch. Patients spent 3 consecutive days in each group with a 4-5 day washout period between treatments. All patients received a single daily dose on their first day. The doses of 3.4 g and 6.8 g were given twice a day on the second and the third day. The dose of 10.2 g was given only once a day. All patients started the study receiving only 1 dose of psyllium fibre on the first day before breakfast to assess the potential impact of 3 single different doses on satiety responses. Three Satiety endpoints were self assessed every half hour for a total of 19 per day: hunger and desire to eat on independent Visual Analog Scales (VAS) and hunger/fullness on the Satiety Labeled Intensity Magnitude (SLIM) scale.
††Scores averaged across all post-prandial measurement times and days were lower significantly or directionally (p ≤ 0.025 and p ≤ 0.052, respectively) for all psyllium doses vs. placebo.
‡‡ Study 2: A randomized, double-blind, placebo-controlled, 2-treatment, 3-period cross-over with a new group of patients. Forty-four healthy patients (25 men/19 women) were enrolled and 40 completed the study. Patients took 6.8 g of psyllium or placebo before receiving an energy restricted breakfast. 6.8 g psyllium or placebo was given before lunch on days 1 & 2 but no dose before lunch on day 3. On each dosing day, patients consumed a breakfast providing an energy equivalent to 15%-20% of their estimated individual resting energy expenditure, but with the same proportions of carbohydrates, protein, and fibre as study 1 (50% carbohydrate, 34% fat, 16% protein). Satiety endpoints were assessed every 30 minutes by self-ratings of hunger and desire to eat on independent Visual Analog Scales (VAS) and hunger/fullness on the Satiety Labeled Intensity Magnitude (SLIM) scale.
RECOMMEND METAMUCIL FOR CHOLESTEROL-LOWERING & APPETITE SUPPRESSION
#1 DOCTOR RECOMMENDED FIBRE BRAND FOR 6 YEARS IN A ROW‡
‡Among recommendations in ProVoice™ surveys 2015 to 2020 (OTC Bulk Fibre category).